Farxiga Significantly Reduced Hospitalization For Heart Failure Or Cv Death In A Broad Patient Population With Type 2 Diabete | Latest News RSS feed

Farxiga Significantly Reduced Hospitalization For Heart Failure Or Cv Death In A Broad Patient Population With Type 2 Diabete - Latest News


FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabete...

AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA (dapagliflozin). The data were presented as a late-breaking abstract (# ... read more

AstraZeneca Group plc (AZN) CEO Pascal Soriot on Q3 2018 Results - Earnings Call Transcript

New CVRM was up by 12%, with Brilinta up 18% and Farxiga up 32%. Respiratory was up by 2% ... endpoint of hospitalization for heart failure or cardiovascular death in a broad population. read more

Doctors Debate Danger Of Popular Diabetes Drug After FDA Amputation Warning

The Scripps Health system’s hospital ... with type 2 diabetes,” she said. The drug “significantly reduced the combined risk of cardiovascular death, nonfatal myocardial infarction (heart attack) and n... read more

Looking for another news?


Astrazeneca PLC (AZN) Q1 2018 Earnings Conference Call Transcript

In CVRM, Farxiga was accepted for review in the EU in Type ... of all-cause death, lower risk of hospitalization for heart failure, lower risk of myocardial infarction and lower risk of stroke. As a r... read more


2017 Brands of the Year: 5 Impact Areas

Patient ... in adults with type 2 diabetes (T2D); in its supplemental new drug applications, BI/Lilly sought a new indication that Jardiance also decreased the incidence of CV death and the risk of de... read more

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes

1 Translational Research Institute for Metabolism and Diabetes, Florida Hospital ... and considering patient convenience and personal choices, it appears that SGLT2 inhibitors would be a reasonable al... read more

AstraZeneca: Q1 2017 Results

Continued good progress on cost control, reflecting the evolving shape of the business: - Reported R&D costs declined by 2% (up by 2% at CER) to $1,453m; Core R&D costs declined by 6% (3% at CER) to $... read more

AZN: 1st Quarter Results

FY 2016 Currency Impact Based on average exchange rates in the quarter and the Company's published currency sensitivities, an adverse full-year impact of around 2% from currency movements on Total Rev... read more

FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial

The reduction in hHF or CV death was consistent across the entire patient population, which included those with CV risk factors and those with established CV disease. 1 FARXIGA is not indicated to red... read more

AZN: H1 2016 Results

Core EPS is now expected to benefit from currency movements by a low to mid single-digit percentage versus ... Forthcoming Major Newsflow Innovation is critical to addressing unmet patient needs and i... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us